Meeting
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).
Authors
Colin P Bergstrom
Stanford University Medical Center, Stanford, CA
Colin P Bergstrom , Hong Song , Shann Mika Ruiz , Joanne Chien , Kaidi Moore , Divya Ahuja Parikh , Sumit Shah , Alice C. Fan , Sandy Srinivas , Andrei Iagaru , Ali Raza Khaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 86)
DOI
10.1200/JCO.2024.42.4_suppl.86
Abstract #
86
Poster Bd #
D1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Soumaya Labidi
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
First Author: Daniel Triner
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2023 ASCO Genitourinary Cancers Symposium
![VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T.](https://d201v5jt9ylckg.cloudfront.net/298/15313/217246/217246_A262_poster_pv.jpg)
VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T.
First Author: James Patrick Buteau